TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1903999

Group type: EXPERIMENTAL
Intervention: Trisdine bladder instillations
Number of subjects: 37

Group type: COMPARATOR
Intervention: O'Neil catheter
Number of subjects: 37
Study: 7362956

Group type: EXPERIMENTAL
Intervention: Short peroperative course of cefamandole
Number of subjects: 79

Group type: COMPARATOR
Intervention: 3-day course of cephradine (Control)
Number of subjects: 79
Study: 29584458

Group type: EXPERIMENTAL
Intervention: Cilnidipine (10 mg/day) for 12 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study: 27649776

Group type: EXPERIMENTAL
Intervention: Ethanol + Brivaracetam
Number of subjects: 18
Study: 26095381

Group type: EXPERIMENTAL
Intervention: Buffered 4% articaine with 1:100,000 epinephrine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nonbuffered 4% articaine with 1:100,000 epinephrine
Number of subjects: 80
Study: 23220077

Group type: EXPERIMENTAL
Intervention: One-day water-only fast
Number of subjects: 30
Study: 21740600

Group type: EXPERIMENTAL
Intervention: Universal goniometer
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Electronic inclinometer
Number of subjects: 7
Study: 19095862

Group type: EXPERIMENTAL
Intervention: Airway Scope
Number of subjects: 100

Group type: COMPARATOR
Intervention: StyletScope
Number of subjects: 100
Study: 16480350

Group type: EXPERIMENTAL
Intervention: 10 mg.kg(‐1) methylprednisolone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 34
Study: 15219505

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 100
Study: 11963730

Group type: EXPERIMENTAL
Intervention: Heparin during acute therapy of AMI
Number of subjects: 22697

Group type: COMPARATOR
Intervention: No heparin during acute therapy of AMI
Number of subjects: 22697

Group type: EXPERIMENTAL
Intervention: Heparin with fibrinolysis
Number of subjects: 22697

Group type: COMPARATOR
Intervention: No heparin with fibrinolysis
Number of subjects: 22697
Study: 9828755

Group type: EXPERIMENTAL
Intervention: CHOred
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: FATred
Number of subjects: 8

Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 8
Study: 7656462

Group type: EXPERIMENTAL
Intervention: Non-insulin-dependent diabetes mellitus
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (sex- and age-matched)
Number of subjects: 200
Study: 2566219

Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pain-Track (FPNVS)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Histamine injection (increasing concentration)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Histamine injection (decreasing concentration)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Flare measurement
Number of subjects: 38
Study: 827779

Group type: EXPERIMENTAL
Intervention: Imipramine (50 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nomifensine (50 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7034467

Group type: EXPERIMENTAL
Intervention: Brief Care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 0
Study: 31726990

Group type: EXPERIMENTAL
Intervention: Interpreter proxy
Number of subjects: 85

Group type: COMPARATOR
Intervention: Certified healthcare interpreter
Number of subjects: 85
Study: 29388532

Group type: EXPERIMENTAL
Intervention: Perception study using food photos for portion estimation
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Memory study using food photos for portion estimation
Number of subjects: 365
Study: 26810496

Group type: EXPERIMENTAL
Intervention: Adjustable, custom-made oral appliance (Narval®) without elastic bands
Number of subjects: 10

Group type: COMPARATOR
Intervention: Adjustable, custom-made oral appliance (Narval®) with elastic bands
Number of subjects: 10

Group type: COMPARATOR
Intervention: Subjects with severe OSA using elastic bands
Number of subjects: 10

Group type: COMPARATOR
Intervention: Overall preference of patients
Number of subjects: 10
Study: 25209323

Group type: EXPERIMENTAL
Intervention: Action 3:30 intervention (40 one-hour sessions, delivered twice a week by teaching assistants)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (10 schools)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Action 3:30 intervention
Number of subjects: 20
Study: 21831453

Group type: EXPERIMENTAL
Intervention: Family-assisted social cognitive training (F-SCIT) once a week for 14 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social stimulation (SS) once every three weeks for 14 weeks
Number of subjects: 0
Study: 20173480

Group type: EXPERIMENTAL
Intervention: Foley catheter removed on postoperative day 1 (Group A)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Foley catheter removed on postoperative day 3 (Group B)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Foley catheter removed on postoperative day 5 (Group C)
Number of subjects: 118
Study: 17018708

Group type: EXPERIMENTAL
Intervention: CHOEP (CHOP+etoposide)
Number of subjects: 1693

Group type: EXPERIMENTAL
Intervention: Intrathecal prophylaxis
Number of subjects: 1693

Group type: COMPARATOR
Intervention: Combination chemotherapy (CHOP-21, CHOP-14)
Number of subjects: 1693

Group type: EXPERIMENTAL
Intervention: Increased LDH and involvement of more than one extranodal site
Number of subjects: 1693

Group type: EXPERIMENTAL
Intervention: Elderly patients with elevated LDH and extranodal involvement
Number of subjects: 1693
Study: 16326641

Group type: EXPERIMENTAL
Intervention: PALM-diet
Number of subjects: 27

Group type: COMPARATOR
Intervention: TRANS-diet
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: PUFA-diet
Number of subjects: 27
Study: 12391522

Group type: EXPERIMENTAL
Intervention: NasOral((R)) system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Face mask with O(2) flow of 15 l/min
Number of subjects: 40
Study: 10445069

Group type: EXPERIMENTAL
Intervention: Dental appliance
Number of subjects: 95

Group type: COMPARATOR
Intervention: UPPP
Number of subjects: 95
Study: 7597662

Group type: EXPERIMENTAL
Intervention: Phosphoramidon (10(‐5) M, 3 ml)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Phosphoramidon
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2205358

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 480 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA)
Number of subjects: 40
Study: 761002

Group type: EXPERIMENTAL
Intervention: 99mtechnetium-labelled red-cell venous pool scanning
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional x-ray phlebography
Number of subjects: 32
Study: 31958907

Group type: EXPERIMENTAL
Intervention: Metformin (1,000 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30311850

Group type: EXPERIMENTAL
Intervention: Internet-facilitated cognitive behavioral therapy (Mom-Net)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 336

Group type: COMPARATOR
Intervention: Motivational interviewing and referral to services
Number of subjects: 336
Study: 28182706

Group type: EXPERIMENTAL
Intervention: Quarterly $70 gift card financial incentives
Number of subjects: 72
Study: 25817108

Group type: EXPERIMENTAL
Intervention: Warm ischemia
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cold ischemia
Number of subjects: 120
Study: 24250317

Group type: EXPERIMENTAL
Intervention: Drain use after thyroidectomy
Number of subjects: 68

Group type: COMPARATOR
Intervention: No drain after thyroidectomy
Number of subjects: 68
Study: 21358565

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Extraversion
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Agreeableness
Number of subjects: 237

Group type: COMPARATOR
Intervention: Context knowledge, context experience, and other personality traits
Number of subjects: 237
Study: 19554002

Group type: EXPERIMENTAL
Intervention: Structured exercise program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 16804289

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patients with OSAS before CPAP treatment
Number of subjects: 80
Study: 15495826

Group type: EXPERIMENTAL
Intervention: Cs A + pred + BLC
Number of subjects: 121

Group type: COMPARATOR
Intervention: Cs A + pred + azathioprine (Aza)
Number of subjects: 121
Study: 11597850

Group type: EXPERIMENTAL
Intervention: Classroom teaching supplemented with Internet-based discussions (Internet component group)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Classroom teaching alone (traditional group)
Number of subjects: 127
Study: 9230238

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 microg x day(-1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg x day(-1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (200 microg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg x day(-1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 400 microg x day(-1)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (400 microg)
Number of subjects: 48
Study: 7975415

Group type: EXPERIMENTAL
Intervention: Element diet
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 19
Study: 3548637

Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride (134 +/- 33 mg/d)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 30724853

Group type: COMPARATOR
Intervention: Conventional DAPT
Number of subjects: 1327

Group type: COMPARATOR
Intervention: Prospective genotyping-guided DAPT
Number of subjects: 1327
Study: 28864691

Group type: EXPERIMENTAL
Intervention: RDN using 5F saline‐irrigated radiofrequency ablation (RFA) plus antihypertensive medication
Number of subjects: 254

Group type: COMPARATOR
Intervention: Antihypertensive medication alone
Number of subjects: 254
Study: 26004401

Group type: EXPERIMENTAL
Intervention: Palliative oxygen
Number of subjects: 226

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 226
Study: 23195627

Group type: EXPERIMENTAL
Intervention: Heart transplant recipients (HTRs)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Healthy controls (CTL)
Number of subjects: 6
Study: 20950844

Group type: EXPERIMENTAL
Intervention: Chewing gum (Group AII and Group BII)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chewing gum (Group AII)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chewing gum (Group BII)
Number of subjects: 60
Study: 18814217

Group type: EXPERIMENTAL
Intervention: Simple-use TAXUS stent (on-label)
Number of subjects: 2487

Group type: COMPARATOR
Intervention: Expanded use TAXUS stent
Number of subjects: 2487
Study: 16051211

Group type: EXPERIMENTAL
Intervention: Normal spatial and temporal structure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scrambled spatial and normal temporal structure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normal spatial and scrambled temporal structure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scrambled spatial and temporal structure
Number of subjects: 0
Study: 13679934

Group type: EXPERIMENTAL
Intervention: 5% albumin (ALB)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 41
Study: 11023499

Group type: EXPERIMENTAL
Intervention: Detectable MRD (ie, > or = 0.01% leukemic mononuclear cells) at each time point
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: High levels of MRD at the end of the induction phase (> or = 1%) or at week 14 of continuation therapy (> or = 0.1%)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: MRD at the end of the induction phase
Number of subjects: 195

Group type: COMPARATOR
Intervention: MRD became undetectable
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Persistence of MRD until week 32
Number of subjects: 195
Study: 8612107

Group type: EXPERIMENTAL
Intervention: Ibuprofen (1800 mg per day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 1595324

Group type: EXPERIMENTAL
Intervention: 0.5 IU.kg‐1.week‐1 hGH
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 1.0 IU.kg‐1.week‐1 hGH
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 46
Study: 6096282

Group type: EXPERIMENTAL
Intervention: Glucomannan fiber (1-g doses, two 500 mg capsules with 8 oz water, 1 h prior to each meal)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Glucomannan fiber
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31714253

Group type: EXPERIMENTAL
Intervention: Online recruitment methods
Number of subjects: 655

Group type: COMPARATOR
Intervention: Traditional recruitment methods
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Online recruitment (Gumtree)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Online recruitment (email)
Number of subjects: 655

Group type: EXPERIMENTAL
Intervention: Gender (Women)
Number of subjects: 655
Study: 29454678

Group type: EXPERIMENTAL
Intervention: 120 mg CoQ10 daily for 24 weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 25426516

Group type: EXPERIMENTAL
Intervention: Resistance Exercise at 0700 hours (7A)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Resistance Exercise at 1300 hours (1P)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Resistance Exercise at 1900 hours (7P)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (7A, 1P, 7P)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Non-Resistance Exercise Control (C)
Number of subjects: 9
Study: 23293082

Group type: EXPERIMENTAL
Intervention: Rituximab + Dexamethasone (40 mg/day for 4 days and 375 mg/m² weekly for 4 weeks)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Dexamethasone (40 mg/day for 4 days)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Rituximab + Dexamethasone
Number of subjects: 133
Study: 21624649

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (15 days with tapering schedule) plus oral amoxicillin/clavulanate (AMX/C)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral amoxicillin/clavulanate (AMX/C) plus placebo
Number of subjects: 48
Study: 19372358

Group type: EXPERIMENTAL
Intervention: C7 landmark
Number of subjects: 210

Group type: COMPARATOR
Intervention: Scapular landmark
Number of subjects: 210
Study: 16456411

Group type: EXPERIMENTAL
Intervention: Prepackaged diet kit plus magnesium citrate/bisacodyl laxative (group 1)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Clear liquids and sodium phosphate solution (group 2)
Number of subjects: 62
Study: 14671241

Group type: EXPERIMENTAL
Intervention: Patients with occipital lobe infarct
Number of subjects: 47

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 47
Study: 11816867

Group type: EXPERIMENTAL
Intervention: Mirtazapine (40 weeks of double-blind continuation-phase therapy)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo (40 weeks of double-blind continuation-phase therapy)
Number of subjects: 410
Study: 7970537

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (Healon)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control (no Healon)
Number of subjects: 107
Study: 3630598

Group type: EXPERIMENTAL
Intervention: Reflective blanket
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Heating humidifier of inhaled gases
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination of both techniques
Number of subjects: 28

Group type: COMPARATOR
Intervention: No prevention at all
Number of subjects: 28
Study: 29338585

Group type: EXPERIMENTAL
Intervention: Family-based media literacy curriculum (six-session curriculum)
Number of subjects: 100
Study: 27594150

Group type: EXPERIMENTAL
Intervention: Conventional therapy combined with treatment for ameliorating the PE symptom (oral dapoxetine on-demand and ejaculation control exercise)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional therapy (oral administration of antibiotics, α-receptor blocker, and proprietary Chinese medicine)
Number of subjects: 90
Study: 25751697

Group type: EXPERIMENTAL
Intervention: ASSRthr (auditory steady-state response threshold)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ASSRthr
Number of subjects: 24
Study: 23868273

Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg intravenously, administered 12 hourly for a total of 5 doses
Number of subjects: 95

Group type: COMPARATOR
Intervention: No minocycline (control)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Meta-analysis of minocycline across 3 human trials
Number of subjects: 95
Study: 20082104

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (Aluminum gallium arsenide laser, 785 nm, 3 J/cm², 70 mW)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo laser
Number of subjects: 82
Study: 18194335

Group type: EXPERIMENTAL
Intervention: Inorganic polyphosphate
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control
Number of subjects: 33
Study: 16474990

Group type: EXPERIMENTAL
Intervention: Early intervention provided between ages 0 and 3
Number of subjects: 985

Group type: COMPARATOR
Intervention: Control group (children without verbal LD)
Number of subjects: 985
Study: 12816140

Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) restorations
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional amalgam restorations
Number of subjects: 89
Study: 11388500

Group type: EXPERIMENTAL
Intervention: Nitroderivative therapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Untreated Chagas patients
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Treated Chagas patients
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Chagas patients (treated and untreated)
Number of subjects: 91
Study: 9356879

Group type: COMPARATOR
Intervention: Cimetidine 300 mg i.v. bolus followed by 300 mg i.v. every 6 hr during hospitalization
Number of subjects: 52

Group type: COMPARATOR
Intervention: Heater probe thermocoagulation + cimetidine 300 mg i.v. bolus followed by 300 mg i.v. every 6 hr during hospitalization
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg i.v. bolus followed by 40 mg i.v. daily for two days
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg i.v. bolus followed by 40 mg i.v. every 12 h for two days
Number of subjects: 52
Study: 8146390

Group type: EXPERIMENTAL
Intervention: 500 mg of mefloquine every month
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 250 mg of mefloquine every two weeks
Number of subjects: 122

Group type: COMPARATOR
Intervention: 500 mg sulphadoxine + 25 mg pyrimethamine (Fansidar) a week
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 3524176

Group type: EXPERIMENTAL
Intervention: Combined probucol (1 g/day) and colestipol (20 g/day)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Modified probucol-colestipol therapy (half-dose of colestipol)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combined probucol-colestipol therapy after 1 and 3 years
Number of subjects: 71

Group type: COMPARATOR
Intervention: Single-drug administration of probucol or colestipol
Number of subjects: 71
Study: 30182113

Group type: EXPERIMENTAL
Intervention: Lactoferrin (LF) supplementation, 3 tablets per day (250 mg per tablet) for 30 days
Number of subjects: 19
Study: 26813357

Group type: EXPERIMENTAL
Intervention: ISA101 vaccination with 5% imiquimod at the vaccine site
Number of subjects: 43

Group type: COMPARATOR
Intervention: ISA101 only
Number of subjects: 43
Study: 24840349

Group type: EXPERIMENTAL
Intervention: Early detection and treatment by community health workers using rapid diagnostic technology
Number of subjects: 2884

Group type: EXPERIMENTAL
Intervention: Community-supported larviciding
Number of subjects: 2884

Group type: EXPERIMENTAL
Intervention: Early detection and treatment plus larviciding
Number of subjects: 2884

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2884
Study: 23835590

Group type: COMPARATOR
Intervention: Intrathecal gabapentin 0 mg/day (placebo)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Intrathecal gabapentin 1 mg/day
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Intrathecal gabapentin 6 mg/day
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Intrathecal gabapentin 30 mg/day
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Intrathecal gabapentin (all doses)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Device-related adverse events
Number of subjects: 170
Study: 20455960

Group type: EXPERIMENTAL
Intervention: Allogenic platelet gel
Number of subjects: 13

Group type: COMPARATOR
Intervention: Current best practice approach to chronic wounds dressing protocol
Number of subjects: 13
Study: 19065861

Group type: EXPERIMENTAL
Intervention: Kinaesthesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Touch alone
Number of subjects: 0
Study: 16169397

Group type: EXPERIMENTAL
Intervention: Long protocol
Number of subjects: 220

Group type: COMPARATOR
Intervention: Short protocol
Number of subjects: 220
Study: 12536327

Group type: EXPERIMENTAL
Intervention: Endoscopic fibrin glue injection
Number of subjects: 61

Group type: COMPARATOR
Intervention: Early elective operation
Number of subjects: 61
Study: 10645753

Group type: EXPERIMENTAL
Intervention: 3 mg tacrolimus
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 7 mg tacrolimus
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg tacrolimus
Number of subjects: 18
Study: 8876707

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB) with zoladex 3.6 mg injection subcutaneous depot monthly and flutamide 250 mg orally three times per day for 2 months, followed by CAB with concurrent XRT (65-70 Gy) for 7-8 weeks
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Zoladex alone for 2 years (Z+ group)
Number of subjects: 141

Group type: COMPARATOR
Intervention: No further treatment (Z- group)
Number of subjects: 141
Study: 1543618

Group type: EXPERIMENTAL
Intervention: Temazepam elixir
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intravenous midazolam
Number of subjects: 15
Study: 3892975

Group type: EXPERIMENTAL
Intervention: Tinidazole (one-shot prophylaxis)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metronidazole (9 doses)
Number of subjects: 100